Showing results (451-460 of 925) with videos related to

Sort By:
Pageof 93
Vaccines|May 7, 2025
The Reduced Immunogenicity of Zoster Vaccines in CMV-Seropositive Older Adults Correlates with T Cell ImprintingAdriana Weinberg, Thao Vu, Michael J Johnson, et al.
Molecular Plant-Microbe Interactions : MPMI|August 10, 2025
Stachydrine Catabolism Contributes to an Optimal Root Nodule Symbiosis Between Sinorhizobium meliloti and Medicago sativaGarrett J Levin, Jason V S Kearsley, Turlough M Finan, et al.
Cureus|November 7, 2022
A Systematic Review and Meta-Analysis Comparing Burn Healing Outcomes Between Silver Sulfadiazine and Aloe veraNicole J Levin, Young Erben, Yupeng Li, et al.
Metabolism: Clinical and Experimental|October 1, 1980
Cortisol production in obesityG W Strain, B Zumoff, J J Strain, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|July 4, 2006
Structural basis of the cross-reaction between an antibody to the Trypanosoma cruzi ribosomal P2beta protein and the human beta1 adrenergic receptorC Smulski, V Labovsky, G Levy, et al.
The Journal of Laboratory and Clinical Medicine|December 1, 1990
Splenic thrombopoiesis after bone marrow ablation with radiostrontium: a murine modelE Davis, L Corash, G Baker, et al.
Antimicrobial Agents and Chemotherapy|February 19, 2002
Susceptibilities of herpes simplex viruses to penciclovir and acyclovir in eight cell linesJeffry J Leary, Robert Wittrock, Robert T Sarisky, et al.
Biochemical and Biophysical Research Communications|October 13, 2007
Mapping of the protein-binding interface between splicing factors SF3b155 and p14 of Trypanosoma cruziM Lara Avila, Natalia Bercovich, Gastón Westergaard, et al.
Viral Immunology|January 1, 1996
Varicella zoster virus-specific cytotoxicity following secondary immunization with live or killed vaccineA R Hayward, K Buda, M Jones, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 1, 1997
Relationship of adverse events to serum drug levels in patients receiving high-dose azithromycin for mycobacterial lung diseaseB A Brown, D E Griffith, W Girard, et al.
Pageof 93